A randomized, open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinum containing chemotherapy

Project: Research

Project Details

Project Description

NMA HREC Reference Number: HREC/18/MonH/196
Monash Health Ref: 18-0000-235A
Effective start/end date12/12/1811/12/23